NEW YORK, Nov. 28 — Silico Insights said Wednesday that it had added three new members to its scientific board of directors, David Schoenfeld , Cathy Wu , and Sudhir Sahasrabudhe .
The company, founded in 2000, is focused on characterizing pathways implicated in cancer.
Sahasrabudhe is executive vice president at Myriad Genetics , and was also a biotechnology chief at Aventis , representing the company for the SNP Consortium .
Schoenfeld is professor of medicine and biostatistics at Harvard Medical School and Harvard School of Public Health , where he directs the clinical coordinating center for a national group conducting trials for Adult Respiratory Distress Syndrome .
Wu is professor of biochemistry and molecular biology at Georgetown ’s medical center, and vice president of the National Biomedical Research Foundation . She led development of the Protein Information Resource sequence database.
The three join Leslie Benet , Mario Schkolnick, and Foster Provost on the company’s scientific advisory board.
Biopure announced Nov. 27 that it had appointed Howard Richman as its vice president for regulatory affairs, and that its senior vice president for medical affairs, Edward Jacobs , Jr. , had stepped down.
Richman will develop a global regulatory strategy for Biopure, which develops and manufactures oxygen therapeutics for use in treating anemia, trauma, ischemic attacks. He will serve as the company’s liaison with regulatory officials and direct all in-house and external regulatory efforts.
Richman, 49, was senior director of regulatory affairs and quality assurance at MacroChem . He has also consulted for the FDA and for the chemical and pharmaceutical industries, with expertise in directing NDAs, BLAs, and laboratory inspections.
Jacobs, who has worked with Biopure since 1984, will continue as a consultant with the company.
Syrrx , the San Diego structural proteomics firm, said Nov. 27 that it had hired Williams Ettouati as its chief business officer. Ettouati will oversee strategic business development at the company and lead efforts to forge new research and discovery alliances.
Ettouati was previously vice president of business development at Aurora Biosciences , and co-founded the Swiss biotech firm GeneProt .
Privately-held Syrrx was founded in 1999 to industrialize the process of determining protein structures.
Visible Genetics said Nov. 21 that David Galloway had joined the company’s board of directors.
Galloway is president and CEO of Torstar , a major Canadian publisher which owns more than 70 community newspapers, a television company and the Harlequin Enterprises romance novel division.
He replaces Robert Prichard , who is president and chief operating officer at Torstar.
Visible Genetics is a Toronto-based pharmacogenomics company that manufactures automated DNA sequencing systems and genotyping kits for infectious diseases and cancer.